Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379051 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
A Phase 1 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT03379051 is a Phase 1 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 78 participants.
The verdict
NCT03379051, a Phase 1 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
Interventions
- DRUG Venetoclax
- DRUG Lenalidomide
- BIOLOGICAL Ublituximab
- DRUG Umbralisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2022-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03379051
The ClinicalTrials.gov registry entry for NCT03379051 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT03379051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03379051 about?
NCT03379051 is a clinical study titled "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL". Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
What is the current status of trial NCT03379051?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2018-03-27. Estimated completion is 2022-06-16.
What interventions are being tested in trial NCT03379051?
The interventions under investigation include: Venetoclax (DRUG), Lenalidomide (DRUG), Ublituximab (BIOLOGICAL), Umbralisib (DRUG).
Who is sponsoring clinical trial NCT03379051?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.